某三级医院新冠肺炎阳性患者疫苗接种效果分析

Q3 Veterinary
Archives of Razi Institute Pub Date : 2024-10-31 eCollection Date: 2024-10-01 DOI:10.32592/ARI.2024.79.5.967
M Nadeem, N Arshad, M Aurang Zeb, S Mushtaq, S Siddiq, J Zeb
{"title":"某三级医院新冠肺炎阳性患者疫苗接种效果分析","authors":"M Nadeem, N Arshad, M Aurang Zeb, S Mushtaq, S Siddiq, J Zeb","doi":"10.32592/ARI.2024.79.5.967","DOIUrl":null,"url":null,"abstract":"<p><p>The SARS-CoV-2, has caused a pandemic of acute respiratory disease, 'coronavirus disease 2019' (Covid-19), posed a major threat to health and the international economy during past few years. It is believed that vaccine can stop the rapid spread of the disease. The aim of this study was to evaluate the effect of the Sinopharm vaccine in terms of mortality and severity of the disease among Covid-19 positive patients. This observational cross-sectional study was done at the Department of Medicine and Department of Pathology Shaikh Khalifa Bin Zayed Al-Nahyan/CMH Teaching Hospital (Poonch Medical College), Rawalakot AJK Pakistan from July 2021 to September 2021. Total 350 individuals with greater than or equal to 18 years of age, who were tested positive for Covid-19, were included. Patients who had received two doses of the vaccine at least 28 days apart were considered as vaccinated. The Sinopharm vaccination status was checked among patients. The severity of Covid-19 was categorized as mild, moderate and severe. A log rank regression test was applied to determine significant difference in disease severity and survival rate. The patients age range was 25-60 years (the patients mean age was 55 years). The majority of participants, 69.1% (n=242), were vaccinated by Sinopharm, and 30.9% (n=108) were non-vaccinated. Most patients had mild disease 80% (n=280) followed by moderate disease 9.7% (n=34), and severe disease 6.6% (n=23), and stratification analysis had significant (p ≤ 0.05) association between vaccinated individuals and disease severity. The overall mortality rate was 3.7%. The mortality rate was 8% (n=9) in none vaccinated individuals, whereas 1.65% (n=4) in vaccinated individuals. The Sinopharm vaccine after both doses was found effective in reducing mortality and disease severity by 98.3% and 94.4%. The study concluded that Sinopharm vaccine after two doses at least 28 days apart given to patients, after two weeks of vaccination is highly effective in reducing the mortality, disease severity and hospital admission in Covid-19 positive patients.</p>","PeriodicalId":8311,"journal":{"name":"Archives of Razi Institute","volume":"79 5","pages":"967-972"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12018730/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of vaccination (Sinopharm) among Covid-19 positive patients in a tertiary care hospital.\",\"authors\":\"M Nadeem, N Arshad, M Aurang Zeb, S Mushtaq, S Siddiq, J Zeb\",\"doi\":\"10.32592/ARI.2024.79.5.967\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The SARS-CoV-2, has caused a pandemic of acute respiratory disease, 'coronavirus disease 2019' (Covid-19), posed a major threat to health and the international economy during past few years. It is believed that vaccine can stop the rapid spread of the disease. The aim of this study was to evaluate the effect of the Sinopharm vaccine in terms of mortality and severity of the disease among Covid-19 positive patients. This observational cross-sectional study was done at the Department of Medicine and Department of Pathology Shaikh Khalifa Bin Zayed Al-Nahyan/CMH Teaching Hospital (Poonch Medical College), Rawalakot AJK Pakistan from July 2021 to September 2021. Total 350 individuals with greater than or equal to 18 years of age, who were tested positive for Covid-19, were included. Patients who had received two doses of the vaccine at least 28 days apart were considered as vaccinated. The Sinopharm vaccination status was checked among patients. The severity of Covid-19 was categorized as mild, moderate and severe. A log rank regression test was applied to determine significant difference in disease severity and survival rate. The patients age range was 25-60 years (the patients mean age was 55 years). The majority of participants, 69.1% (n=242), were vaccinated by Sinopharm, and 30.9% (n=108) were non-vaccinated. Most patients had mild disease 80% (n=280) followed by moderate disease 9.7% (n=34), and severe disease 6.6% (n=23), and stratification analysis had significant (p ≤ 0.05) association between vaccinated individuals and disease severity. The overall mortality rate was 3.7%. The mortality rate was 8% (n=9) in none vaccinated individuals, whereas 1.65% (n=4) in vaccinated individuals. The Sinopharm vaccine after both doses was found effective in reducing mortality and disease severity by 98.3% and 94.4%. The study concluded that Sinopharm vaccine after two doses at least 28 days apart given to patients, after two weeks of vaccination is highly effective in reducing the mortality, disease severity and hospital admission in Covid-19 positive patients.</p>\",\"PeriodicalId\":8311,\"journal\":{\"name\":\"Archives of Razi Institute\",\"volume\":\"79 5\",\"pages\":\"967-972\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12018730/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Razi Institute\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32592/ARI.2024.79.5.967\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Veterinary\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Razi Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32592/ARI.2024.79.5.967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Veterinary","Score":null,"Total":0}
引用次数: 0

摘要

SARS-CoV-2引起了急性呼吸道疾病“2019冠状病毒病”(Covid-19)的大流行,在过去几年中对健康和国际经济构成了重大威胁。人们相信疫苗可以阻止这种疾病的迅速传播。本研究的目的是评价国药集团疫苗对Covid-19阳性患者的死亡率和疾病严重程度的影响。这项观察性横断面研究于2021年7月至2021年9月在巴基斯坦拉瓦拉科特的谢赫·哈利法·本·扎耶德·阿勒纳哈扬/CMH教学医院(Poonch医学院)医学部和病理科进行。共纳入350名18岁以上的Covid-19检测呈阳性的个体。相隔至少28天接种两剂疫苗的患者被认为接种了疫苗。对患者进行国药疫苗接种情况检查。新冠肺炎的严重程度分为轻度、中度和重度。采用对数秩回归检验确定疾病严重程度和生存率的显著差异。患者年龄25 ~ 60岁,平均年龄55岁。大多数参与者(69.1%,n=242)接种了国药集团的疫苗,30.9% (n=108)未接种疫苗。其中轻病占80% (n=280),中度病占9.7% (n=34),重度病占6.6% (n=23),分层分析结果显示接种疫苗个体与疾病严重程度有显著相关性(p≤0.05)。总死亡率为3.7%。未接种者死亡率为8% (n=9),而接种者死亡率为1.65% (n=4)。两剂后的国药控股疫苗的死亡率和疾病严重程度分别降低了98.3%和94.4%。该研究得出结论,国药控股的疫苗接种间隔至少28天,接种两周后,在降低Covid-19阳性患者的死亡率、疾病严重程度和住院率方面非常有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effectiveness of vaccination (Sinopharm) among Covid-19 positive patients in a tertiary care hospital.

The SARS-CoV-2, has caused a pandemic of acute respiratory disease, 'coronavirus disease 2019' (Covid-19), posed a major threat to health and the international economy during past few years. It is believed that vaccine can stop the rapid spread of the disease. The aim of this study was to evaluate the effect of the Sinopharm vaccine in terms of mortality and severity of the disease among Covid-19 positive patients. This observational cross-sectional study was done at the Department of Medicine and Department of Pathology Shaikh Khalifa Bin Zayed Al-Nahyan/CMH Teaching Hospital (Poonch Medical College), Rawalakot AJK Pakistan from July 2021 to September 2021. Total 350 individuals with greater than or equal to 18 years of age, who were tested positive for Covid-19, were included. Patients who had received two doses of the vaccine at least 28 days apart were considered as vaccinated. The Sinopharm vaccination status was checked among patients. The severity of Covid-19 was categorized as mild, moderate and severe. A log rank regression test was applied to determine significant difference in disease severity and survival rate. The patients age range was 25-60 years (the patients mean age was 55 years). The majority of participants, 69.1% (n=242), were vaccinated by Sinopharm, and 30.9% (n=108) were non-vaccinated. Most patients had mild disease 80% (n=280) followed by moderate disease 9.7% (n=34), and severe disease 6.6% (n=23), and stratification analysis had significant (p ≤ 0.05) association between vaccinated individuals and disease severity. The overall mortality rate was 3.7%. The mortality rate was 8% (n=9) in none vaccinated individuals, whereas 1.65% (n=4) in vaccinated individuals. The Sinopharm vaccine after both doses was found effective in reducing mortality and disease severity by 98.3% and 94.4%. The study concluded that Sinopharm vaccine after two doses at least 28 days apart given to patients, after two weeks of vaccination is highly effective in reducing the mortality, disease severity and hospital admission in Covid-19 positive patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archives of Razi Institute
Archives of Razi Institute Veterinary-Veterinary (all)
CiteScore
1.50
自引率
0.00%
发文量
108
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信